ADDoPTing a new approach to pharmaceuticals
06 Feb 2017
Yes
-  

 

 

​We are excited to have a key role in a new £20.4m project which will transform the UK pharmaceutical industry

 

​​​Credit: iStock

 

​We are excited to have a key role in a new £20.4m project which will transform the UK pharmaceutical industry by enabling the future design of innovative medicine manufacturing processes to be done digitally.

ADDoPT (Advanced Digital Design of Pharmaceutical Therapeutics) is a pioneering four-year collaboration between government, industry and academia which will tackle the challenge of getting new innovative medicines to market in the quickest and most cost-effective way possible to ensure the earliest access for patients.

This will be done by developing advanced digital design techniques that that eliminate non-viable drug candidate formulations as early as possible, streamlining design, development and manufacturing processes.

Industrial pharmaceutical project partners such as Pfizer, GSK, AstraZeneca and Bristol-Myers Squibb will provide case studies, to which we will apply our expertise in supercomputing, big data analytics and computational chemistry. In this way we hope to develop more accurate digital design techniques that will enable more of the early R&D process to be carried out virtually, saving time and improving cost efficiency.

For more information about the ADDoPT project contact Adrian Toland, Business Development Manager

 


Contact: